Postprandial secretion of follistatin after gastric bypass surgery and sleeve gastrectomy
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Postprandial secretion of follistatin after gastric bypass surgery and sleeve gastrectomy. / Richter, Michael M; Svane, Maria S; Kristiansen, Viggo B.; Holst, Jens J.; Madsbad, Sten; Bojsen-Møller, Kirstine N.
In: Peptides, Vol. 163, 170978, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Postprandial secretion of follistatin after gastric bypass surgery and sleeve gastrectomy
AU - Richter, Michael M
AU - Svane, Maria S
AU - Kristiansen, Viggo B.
AU - Holst, Jens J.
AU - Madsbad, Sten
AU - Bojsen-Møller, Kirstine N
N1 - Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2023
Y1 - 2023
N2 - Follistatin is secreted from the liver and may regulate muscle growth and insulin sensitivity. Protein intake stimulates follistatin secretion, which may be mediated by increased glucagon in the context of low insulin concentrations. We investigated circulating follistatin after mixed-meals in two cohorts of patients who were part of previously published studies and had undergone bariatric surgery with either simultaneous assessment of amino acid absorption or administration of the GLP-1 receptor antagonist exendin-(9-39), which increased glucagon concentrations and impaired insulin secretion. Study 1 comprised obese matched subjects with previous Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) surgery and unoperated controls who underwent 6-hour mixed-meal tests with intravenous and oral tracers including intrinsically labelled caseinate in the meal. Study 2 comprised obese subjects with previous RYGB who underwent two 5-hour mixed-meal tests with concomitant exendin-(9-39) or saline infusion. In study 1, the secretion of follistatin as well as the amino acid absorption was accelerated after RYGB compared with SG and controls, but the glucagon-to-C-peptide ratios did not differ between the groups. In study 2, exendin-(9-39) administration increased postprandial glucagon concentrations and lowered insulin secretion, whereas the concentration of follistatin was unchanged. In conclusion, postprandial follistatin secretion is accelerated in patients after RYGB which might be explained by an accelerated protein absorption rate rather than the glucagon-to-insulin ratio.
AB - Follistatin is secreted from the liver and may regulate muscle growth and insulin sensitivity. Protein intake stimulates follistatin secretion, which may be mediated by increased glucagon in the context of low insulin concentrations. We investigated circulating follistatin after mixed-meals in two cohorts of patients who were part of previously published studies and had undergone bariatric surgery with either simultaneous assessment of amino acid absorption or administration of the GLP-1 receptor antagonist exendin-(9-39), which increased glucagon concentrations and impaired insulin secretion. Study 1 comprised obese matched subjects with previous Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) surgery and unoperated controls who underwent 6-hour mixed-meal tests with intravenous and oral tracers including intrinsically labelled caseinate in the meal. Study 2 comprised obese subjects with previous RYGB who underwent two 5-hour mixed-meal tests with concomitant exendin-(9-39) or saline infusion. In study 1, the secretion of follistatin as well as the amino acid absorption was accelerated after RYGB compared with SG and controls, but the glucagon-to-C-peptide ratios did not differ between the groups. In study 2, exendin-(9-39) administration increased postprandial glucagon concentrations and lowered insulin secretion, whereas the concentration of follistatin was unchanged. In conclusion, postprandial follistatin secretion is accelerated in patients after RYGB which might be explained by an accelerated protein absorption rate rather than the glucagon-to-insulin ratio.
KW - Humans
KW - Glucagon/metabolism
KW - Gastric Bypass
KW - Blood Glucose/metabolism
KW - Follistatin
KW - Insulin/metabolism
KW - Obesity/surgery
KW - Gastrectomy
KW - Amino Acids
U2 - 10.1016/j.peptides.2023.170978
DO - 10.1016/j.peptides.2023.170978
M3 - Journal article
C2 - 36842630
VL - 163
JO - Peptides
JF - Peptides
SN - 0196-9781
M1 - 170978
ER -
ID: 340116535